drugset
Drugs / Quadrivalent VLP Influenza Vaccine
last change Apr 2022 re-read 9 days ago

Quadrivalent VLP Influenza Vaccine

also known as Quadrivalent virus-like particle (VLP) Influenza Vaccine

Vaccine

Developed for
influenza
Investigated by
Medicago

Trials 2

today NCT04622592 · Ph 1/2 NCT03321968 · Ph 3
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT04622592 Nov 2020 → Apr 2022 influenza Medicago Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT03321968 Sep → Dec 2017 influenza Medicago Completed Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Quadrivalent VLP Influenza Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03321968 ↗
1

NCT04622592 ↗
Known as Quadrivalent virus-like particle (VLP) Influenza Vaccine “Participants received one intramuscular (IM) injection (total volume 0.7 mL) of 15 μg/strain of the Quadrivalent virus-like particle (VLP) Influenza Vaccine adjuvanted with...” NCT04622592 ↗
Modality Vaccine “a quadrivalent, recombinant, virus-like particle (VLP) influenza vaccine produced in plants.” PMID 33581920 ↗ Feb 2021
Route Intramuscular “one intramuscular (IM) injection” NCT03321968 ↗